Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today reported its financial and operational results for the quarter ended March 31, 2014. The Company’s clinical focus has now evolved to center on patients with genetically defined forms of B-cell lymphoma and on patients with rare autoimmune diseases.
Help employers find you! Check out all the jobs and post your resume.
